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Background Previously, HIV epidemic models have used a double Weibull curve
to represent high initial and late mortality of HIV-infected children,
without distinguishing timing of infection (peri- or post-natally).
With more data on timing of infection, which may be associated
with disease progression, a separate representation of children
infected early and late was proposed.
Methods Paediatric survival post-HIV infection without anti-retroviral treat-
ment was calculated using pooled data from 12 studies with known
timing of HIV infection. Children were grouped into perinatally
or post-natally infected. Net mortality was calculated using
cause-deleted life tables to give survival as if HIV was the only com-
peting cause of death. To extend the curve beyond the available data,
children surviving beyond 2.5 years post infection were assumed
to have the same survival as young adults. Double Weibull curves
were fitted to both extended survival curves to represent survival
of children infected perinatally or through breastfeeding.
Results Those children infected perinatally had a much higher risk of dying
than those infected through breastfeeding, even allowing for back-
ground mortality. The final-fitted double Weibull curves gave 75%
survival at 5 months after infection for perinatally infected, and 1.1
years for post-natally infected children. An estimated 25% of the
early infected children would still be alive at 10.6 years compared
with 16.9 years for those infected through breastfeeding.
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Conclusions The increase in available data has enabled separation of child
mortality patterns by timing of infection allowing improvement
and more flexibility in modelling of paediatric HIV infection and
survival.
Keywords HIV, survival, paediatric
Introduction
Until recently, survival of HIV-infected children in
the absence of causes of death unrelated to HIV
has been modelled using a double Weibull curve
that represents the mortality experienced by
HIV-infected children irrespective of their time of
infection from birth.1,2 The double Weibull curve
has been used as it is one of the few functional
forms that can describe high initial mortality along
with rising mortality at older ages. However, in a
pooled analysis, Newell et al.3 showed that mortality
in the 2 years following infection was lower for
children who acquired HIV via breastfeeding
(post-natal infection) than those with perinatal in-
fection.3 To improve modelling of the HIV epidemic,
a separate representation of children infected early
and late was thus deemed appropriate. Indeed, new
data have become available from clinical trials that
provide information on HIV status of children from
birth and allow an accurate estimation of age at
infection and sufficient follow-up time to allow as-
sessment of the risk of dying. These data are in
accordance with the differences shown by Newell
et al.4
It has been suggested that the impact of age at
infection may be due to background mortality pat-
terns.5 Removing background mortality did have a
slightly larger effect in those infected at older ages
where background mortality is higher but it did not
explain the differences in survival from age at in-
fection in adults. However, such effects are more
extreme in childhood where the differences between
neonatal and post-neonatal mortality are much
greater than the differences in mortality rates in
adults within 1 month or 1–12 months after infec-
tion. Therefore, some of the differences in time
since infection shown by Newell et al.3 might be
attributable to background mortality in the neonatal
period.
This article investigates the effect of background
mortality on survival post infection of children by
time of infection for up to 2.5 years following ac-
quisition of infection. In order to bridge the gap in
the data between children and young adults, sur-
vival curves are further extended beyond the avail-
able data by using survival of young adults and
model curves fitted to the net survival of each of
these groups for use in HIV modelling.
Methods
Data
Data from 12 clinical trials and cohort studies in
Southern, Eastern and Western Africa (Table 1)
were included in a pooled analysis where all the
data were combined into the same data set. Interven-
tions in these studies were various peripartum
anti-retroviral prophylactic regimens,6–14 vitamin A15
and birth canal cleansing.16 These trials represent the
vast majority of the clinical research studies per-
formed since the mid-90s on the African continent
on prevention of mother-to-child transmission of
HIV. Most study sites (n¼ 8) were situated in refer-
ence hospitals of capital or large cities; three studies
were based in antenatal care clinics, or a mixture of
the two, and one in a mixture of both urban and rural
settings. The ZVITAMBO study accounted for 51% of
the person-years of exposure for HIV-infected chil-
dren. The median follow-up time ranged from 300
to 1096 days, and studies tested at regular intervals
in the first 18 months. Some studies explicitly stated
that they provided free medical treatment at time of
follow-up and in between follow-up visits.
Inclusion criteria
Data collected in time periods when anti-retroviral
treatment was widely available cannot be used in
the analysis as they would not represent the survival
from HIV per se. However, it would be incorrect to
censor children at time of treatment initiation as this
would mean we were selecting out those who were
going to die thereby biasing the results to give much
lower mortality. Anti-retroviral treatment became
available in the MASHI trial on 1 October 2002 so
follow-up was rightly censored at this point.
Anti-retroviral treatment was not available during
the time of the other trials.
Mortality analysis
Date of infection was taken to be the midpoint
between the last negative test and the first positive
HIV test (antibody or PCR depending on age). Where
there was no negative test for those infected early,
the midpoint between birth and first positive test
was taken. A sensitivity analysis was undertaken
to assess how results varied according to the date
imputed.
Children were grouped by infection status (infected
and uninfected) and time of infection (perinatal,
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breastfeeding or post-natal period, status unknown)
as defined by Newell et al.3 Those with unknown
timing of infection were not used in the analysis
beyond looking at their overall mortality compared
with those with known timing of infection. Kaplan–
Meier analysis was used to calculate survival curves.
Uninfected children of positive mothers were used to
estimate mortality from non-HIV-related causes when
calculating net survival.
Prior to decisions on pooling data on the effect on
the mortality hazards of the child receiving
anti-retroviral drugs in the first 7 days of life for
PMTCT post-exposure prophylaxis and possible re-
gional differences, a piece-wise Weibull model was
constructed adjusting for duration of follow-up (to
allow for changing composition due to differing
follow-up times across studies) and study of origin
to assess whether data should be excluded or ana-
lysed separately.
Calculating net survival
Methods to calculate paediatric survival have been
described in detail elsewhere.1 In brief, the net sur-
vival probability, lA(x), if HIV-related mortality is the
only operative cause of death, can be calculated from
the proportions of HIV-infected children surviving to
age x, lOþA(x), and the proportion of uninfected chil-
dren surviving to age x, lO(x), using the usual rela-
tionship for cause-deleted life tables:
lAðxÞ ¼ lOþAðxÞ
lOðxÞ
To make the distribution of the HIV-negative children
similar to that of the HIV-infected children, the
HIV-negative ones were weighted so that their distri-
bution by entry into observation, study group and
timing of start of risk exposure matched those of
the HIV-infected children.
Newell et al. showed that infected infants experience
different rates of progression through the disease
stages leading to AIDS and death, with those who
acquired the infection in utero experiencing a more
rapid progression than those acquiring the infection
around the time of delivery or during breastfeeding.
As noted, the double Weibull provides a good func-
tional representation of paediatric survival curve as it
allows for initial high mortality followed by rising
mortality at later time points,1,18 taking the form:
lAðxÞ ¼   exp  1  x½ 1
 þ 1  ð Þ  exp  2  x½ 2
 
By studying the empirical curves depicting net sur-
vival by time since infection we produce two func-
tional representations: one for those with perinatal
infection and one for those with infection through
breastfeeding.
External constraints were introduced to extend the
curve beyond the follow-up time provided by the stu-
dies, and these data were used until 20 subjects were
remaining, which was deemed as a point at which the
results could not be seen as reliable due to small
numbers. Recently, a pooled study has been pub-
lished5,19 showing survival post infection in adults
by age of infection using data from low- and
middle-income countries. This showed a more favour-
able survival for those adults infected at a younger
age, and similar results were found in studies from
higher-income countries in the pre-ART era.20 A rea-
sonable assumption we could thus consider is that the
net HIV mortality rates of infected children at long
durations of infection are no higher than the rates
experienced by HIV-infected young adults below age
25 years. The net survival of adults from HIV is
described by the single Weibull curve:
lAðxÞ ¼ exp½  x
Results
A total of 1930 infected children with known timing
of infection were included in the analysis, contribut-
ing 1576 person years of follow-up. The median age at
last follow-up or death was 1.0 years (range: fraction
of a day to 4.39 years) for infected children and
1.49 years (range: fraction of a day to 11.39 years)
Table 2 Follow-up and outcome by child’s HIV infection status and timing of infection
Number
at start
Total
person-years Deaths
Follow-up in years
Median Maximum
Infected
Perinatally 1340 1095.38 699 0.64 4.39
Through breastfeeding 590 480.66 120 0.65 4.17
Timing unknown 615 590.34 254 0.86 3.77
Uninfected
Mother positive 8384 11 457.84 493 1.49 11.39
Mother negative 1584 2633.18 51 1.83 4.48
Unknown infection status
Mother positive 9484 11 296.43 250 1.02 3.28
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for uninfected children of HIV-positive mothers. Of
the 1930 infected children, timing of infection was
considered early for 1340, late for 590 and unknown
for 615 (Table 2).
Figure 1 shows the cumulative survival of these chil-
dren by timing of infection. Median age of survival
was 348 days for those infected perinatally, but was
not reached by 2.0 years when only 20 subjects
remained for those infected through breastfeeding,
and therefore could not be calculated. The survival
of children for whom the mode of infection was
unknown was intermediate, suggesting that this cat-
egory was made up of children infected perinatally
and through breastfeeding. The mortality hazard of
those children infected through breastfeeding was
0.39 [95% confidence interval (CI) 0.32–0.46], lower
than for those infected perinatally. The mortality data
of uninfected children which are used to compute
non-HIV-related mortality risks for those infected
perinatally, showed, as expected, higher mortality
and worse survival than those of the uninfected
children used to compute the equivalent risks for
those infected through breastfeeding. Mortality of
uninfected children included in these trials was very
low with an overall infant mortality rate of 4 per
1000, i.e. lower than in most sub-Saharan African
populations generally. Changing the imputed infec-
tion date for early infection to be birth for children
who only had a positive, and no negative, test had
almost no effect on the results. This is also true of
the later infected children, assuming the date of in-
fection to be the earliest possible date (last negative
test) or the latest possible date (first positive test)
date.
Differentials by region and peripartum
anti-retroviral treatment
Differences in survival by region and whether the
child received peripartum anti-retroviral intervention
in the first 7 days of life were assessed using
piece-wise Weibull models; these were adjusted for
study. After adjusting for study, no mortality differ-
ences were seen across the regions or between chil-
dren who received peripartum preventative
anti-retroviral treatment in the first 7 days of life
(Table 3).
Timing of late infection
The late infection group was split further into four
groups. A Weibull piece-wise model adjusting for dur-
ation of follow-up and trial showed a decrease in the
gross mortality the later the child is infected
(Table 4). Figure 2 shows the increasing improvement
in survival with later age at infection.
Net survival
Removing all other causes of mortality to give survival
as if HIV was the only cause of death only slightly
raised survival for both those infected perinatally or
through breastfeeding (Figure 3). The resulting net
survival at 1 year post infection for those infected
perinatally was 52% and for those infected through
breastfeeding 78% (Table 5).
Table 3 Hazard ratios (HR) of survival for HIV Infection perinatally and through breastfeeding
Perinatal infection Infection through breastfeeding
Adjusted for duration
of follow-up
Adjusted for duration
of follow-up and study
Adjusted for duration
of follow-up
Adjusted for duration
of follow-up and study
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Region
Eastern Africa 1 1 1 1
Southern Africa 1.60 (1.19–2.16)** 1.54 (0.85–2.82) 0.69 (0.44–1.08) 0.59 (0.20–1.73)
Western Africa 1.39 (0.96–2.01) 1.67 (0.21–13.03) 0.87 (0.44–1.74) 2.19 (0.37–12.92)
Child PMTCT ARV
No 1 1 1 1
Yes 1.22 (1.00–1.49)* 1.20 (0.62–2.34) 0.69 (0.47–1.00)* 0.41 (0.16–1.02)
*P< 0.05; **P< 0.01. ARV, antiretroviral prophylaxis.
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Figure 1 Survival from time of infection by timing of HIV
infection and weighted survival of uninfected children
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Extending the observed net curve
Weibull curves were fitted to the net survival of adults
post infection in East Africa by age at infection which
gave a median time of survival of 20 years for 15- to
24-year olds (l¼ 0.002; ¼ 2.195) decreasing to 14
years for ages 35–44 years (l¼ 0.025, ¼ 1.532).5
Assuming that children who survive for 2.5 years
following perinatal infection and 2 years follow-
ing infection through breastfeeding (the maximum
follow-up time with greater than 20 subjects remain-
ing) do not have a worse survival than young
adults at the equivalent time post infection, the net
curve was extended using the probabilities of
dying between years since infection x and xþ1 for
adults at the same point in time. Double Weibull
curves were then fitted to the extended net survival
(Figure 4).
Table 6 gives a summary of the curve fits to the
extended net survival. The final double Weibull
curves give a median survival at 1.1 years for peri-
natal infection and 9.4 years for infection through
breastfeeding. This predicts a survival of 33% at
5 years from time of infection for those infected
perinatally and 60% for those infected through
breastfeeding. At 20 years, this is 9% and 16%,
respectively.
Discussion
The current analysis produced separate survival
schedules for children infected perinatally and those
infected through breastfeeding, with a median sur-
vival of 1.1 and 9.4 years, respectively. The use of
these updated schedules in mathematical modelling
of the HIV epidemic among children is expected to
constitute a major improvement over the past
approach with a unique survival schedule applied to
all children. This has extended work done by Newell
et al. suggesting a possible mortality difference by
timing of vertical infection by adding new data that
have become available and extending the survival
curves using the net survival of young adults from
HIV. The differences in survival are substantial at 5
years after infection, with only 33% of those infected
perinatally surviving compared with 60% of those in-
fected through breastfeeding. At 20 years after infec-
tion the difference is smaller at 16% compared with
9%; this is mainly because in the absence of evidence
to suggest that either one should be higher we have
applied the same mortality schedule to both groups
after 2.5 years.
The analysis further shows that there are also dif-
ferences in survival within those who are infected
through breastfeeding with a more favourable survival
Table 4 HRs for those with late HIV infection
Adjusted for duration of
follow-up and trial
HR (95% CI)
Region
Eastern Africa 1
Southern Africa 0.57 (0.2–1.67)
Western Africa 2.48 (0.42–14.78)
Peripartum ARV
No 1
Yes 0.4 (0.16–1.01)
Age at infection (days)
28–90 1
90–180 0.81 (0.52–1.27)
180–365 0.53 (0.33–0.85)**
5365 0.16 (0.06–0.42)***
**P< 0.01; ***P< 0.001.
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Figure 2 Survival from time of infection by age at infection
for those infected through breastfeeding
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Figure 3 Net and gross survival from time since infection
for infection perinatally and through breastfeeding
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the later the time of infection, and these differences
still persisted after taking into account background
mortality.
We found no difference between the survival of
those HIV-infected infants treated and not treated
with peripartum anti-retrovirals to prevent mother-
to-child transmission and therefore included these
children in the analysis. We do not question the
effectiveness of PMTCT interventions to reduce the
risk of transmission of HIV. However, our data sug-
gest that where an infant acquires infection in spite of
PMTCT exposure, mortality levels are similar to those
infants infected without exposure to PMTCT. Regional
differences in survival by timing of infection were not
seen once heterogeneity between trials was accounted
for; therefore, with these current data we pooled data
from all regions into the same data set to generate
one curve to represent all children. These data are
only from sub-Saharan Africa with 51% of the
person-years of exposure coming from the
ZVITAMBO trial in Zimbabwe.8 Regional differentials
between sub-Saharan Africa and Thailand were seen
in adults;19 therefore, adding data from other regions
would help confirm whether such differences exist for
the mortality of HIV-positive children, although we
acknowledge that fewer HIV-exposed children are
breastfed in Asia or South America than in
sub-Saharan Africa.
Although breastfeeding is an important factor in
child survival,21 we have not excluded those who
were never breastfed. Without knowing the breast-
feeding trends in the general population we cannot
tell how representative this sample is. Even if we
had excluded this 12% from this analysis, the
impact on the overall highly unfavourable survival
curve would be minimal.
Background mortality had very little effect on the
differences in survival post-infection for both early
Table 5 Probability of survival for HIV-infected children and uninfected children to time by timing of infection
Time
1 day 7 days 28 days 90 days 180 days 1 year 2 years 2.5 years
Perinatal infection
Uninfected (weighted) 1 1 0.99 0.96 0.95 0.93 0.92 0.91
Infected 1 1 0.98 0.80 0.64 0.49 0.35 0.32
Net survival 1 1 0.99 0.83 0.67 0.52 0.39 0.35
Net Weibull 0.99 0.96 0.9 0.79 0.69 0.54 0.37 0.32
Infection through breastfeeding
Uninfected (weighted) 1 1 1 0.99 0.98 0.97 0.96 0.96
Infected 1 1 0.99 0.96 0.88 0.76 0.62 0.58
Net survival 1 1 1 0.97 0.89 0.78 0.64 0.60
Net Weibull 1 0.99 0.98 0.94 0.89 0.79 0.63 0.56
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Figure 4 Double Weibull curves fitted to extended net
survival functions for early and late HIV infection. Curves
were fitted using the net probability of survival of adults age
15–24 years after 2.5 years of follow-up for perinatal infec-
tion and 2.0 years for those infected through breastfeeding
Table 6 Summary of curve fits to the extended net survival (using adult survival) for those infected with HIV perinatally
and through breastfeeding from time of infection
Time of infection
Parameters Percentiles
Net mortality
risks (per thousand)
 l1 1 l2 2 75% 50% 25% 1q0 5q0
Perinatal 0.65 1.34 1.06 0.06 2.19 0.38 1.09 10.61 481 626
Breastfeeding 0.35 1.03 1.66 0.06 2.19 1.09 9.24 16.91 232 396
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and late infection. All the data come from clinical
trials or research studies within which background
mortality, taken from the uninfected children of
infected mothers, apparently was much lower than
in the corresponding communities. The overall HIV-
negative infant mortality rate in the current analysis
was 4 per 1000. The Demographic and Health
Surveys22 give infant mortality rates in the 10 years
preceding each survey. Estimates for urban areas
ranged from 41 in South Africa 2003 to 72 in
Tanzania in 2004–05, all indicating a much higher
mortality in the general population in many of the
places the trials took place. The difference is evident
even if we allow for the fact that the DHS figure in-
cludes the mortality of HIV-infected children and that
the studies mainly took place at the later end of these
periods (i.e. if infant mortality decreases over time we
would expect a lower mortality rate in the trial). It
strongly suggests that the mortality of uninfected
children involved in the trials is lower than that in
the general population, possibly due to increased
access to healthcare services due to study participa-
tion; therefore, in the general population one might
expect to see a larger difference between net and
gross mortality.
We have used the mortality of HIV-negative children
of positive mothers as a reference in this analysis.
Therefore the resulting net mortality does not take
into account the added negative effect of having an
HIV-positive mother. There is evidence to suggest that
there is a difference in the mortality of HIV-negative
children born to HIV-positive mothers compared with
HIV-negative mothers. The Rakai study23 found that
overall, for those <2 years of age, C(x< 2)¼ 1.3,
where C(x) is the ratio between uninfected children
of infected mothers compared with those of uninfect-
ed mothers at age x, but there was some evidence
of variation of C(x) with age, with C(x< 1)¼ 1.1,
and C(1 < x< 2)¼ 1.8. A study in Kampala24
showed a similar pattern with the same overall
value for C(x< 2)¼ 1.3 and a similar increase with
age on subdivision of the interval.
The model curves beyond 2.5 years rely on what is
known about adult survival and assume that children
are like younger adults with respect to mortality pat-
terns. Further investigation is needed about whether
this is a valid assumption, especially for children in-
fected early. The inclusion of more data from other
trials might increase our knowledge of net child sur-
vival beyond 2.5 years and give a more accurate pic-
ture and more knowledge on how child survival
compares with young adult survival. However these
data are currently scarce and with the increase in
antiretroviral treatment in children it is unlikely that
any further data will become available. It is possible
that data on time to treatment need and time to
death from treatment by timing of infection might
help inform us further.
The aim of this analysis was to improve modelling
of the HIV epidemic by providing a separate represen-
tation of children infected perinatally and through
breastfeeding. This analysis is an update on work
done previously1,2 and has used more detailed data
from studies that can provide the timing of HIV in-
fection of a child.
The increase in data available and the construction
of separate survival curves for children infected peri-
natally and through breastfeeding allow for a clear
improvement in the modelling of the HIV epidemic
and is being used in the UNAIDS spectrum package
to project the HIV epidemic.25
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KEY MESSAGES
 Children infected perinatally with HIV have a much higher risk of dying than those infected through
breastfeeding.
 Differences seen in the survival of children infected perinatally with HIV and through breastfeeding
cannot be explained by differences in background mortality, which is much higher in the neonatal
period.
 The use of two separate curves to describe the net survival from perinatal and breastfeeding HIV
infection improves the realism of child survival when modelling the HIV epidemic.
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